Patents Examined by Nora M. Rooney
-
Patent number: 11970538Abstract: The present disclosure relates to compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression. In some embodiments, provided herein are compositions that block the interaction between PD-1 and its ligand (e.g., PD-1 and/or PD-L2) while promoting the interaction of the cells on which PD-1 and its ligand are expressed. Also provided are methods of using such compositions.Type: GrantFiled: May 20, 2021Date of Patent: April 30, 2024Assignee: COMPASS THERAPEUTICS LLCInventors: Bing Gong, Rachel Rennard, Amanda Frank Oliphant, Cheuk Lun Leung, Benjamin Jacob Wolf, Ugur Eskiocak, Pearl Bakhru, Diana I. Albu
-
Patent number: 11965020Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.Type: GrantFiled: May 17, 2023Date of Patent: April 23, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chia-Yang Lin, Samuel Davis
-
Patent number: 11965026Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.Type: GrantFiled: June 20, 2017Date of Patent: April 23, 2024Assignee: KYMAB LIMITEDInventors: Jamie Campbell, Nikole Sandy, Cassandra Van Krinks, Stephen John Arkinstall, Volker Germaschewski, Ian Kirby, Miha Kosmac, Thomas Gallagher, Cecilia Deantonio, Stephen Douglas Gillies
-
Patent number: 11946074Abstract: Compositions and methods are provided for making and using a cell having expressed on its outer plasma membrane surface an Anchor designed to form a first complex with a selected Linker. The Linker is designed to form a second complex with in a target protein that is not recognized by the Anchor. These cells can be primary cells or immortalized cells, they function as fusion partners to create hybridoma cells. The cells can be designed to bind a secreted targeted protein, e.g., a secreted antibody, to the cell surface via an immune complex formed by the Anchor-Linker and permit the identification of the existence, antigen specificity, and antigen binding affinity, titer, amount, or biological activity of the target protein. In certain embodiments, the Linker is of a species heterologous to the species of the Anchor; and the target protein is of a species heterologous to the Linker and to the Anchor.Type: GrantFiled: March 23, 2018Date of Patent: April 2, 2024Assignee: Lankenau Institute for Medical ResearchInventors: Scott K. Dessain, Rama Devudu Puligedda
-
Patent number: 11926651Abstract: The present invention relates to a polypeptide construct comprising at least two fragments of an allergen from the Amb a 1 family of allergens from Ambrosia atermisiifolia or variants of said at least two fragments, wherein each of the at least two fragments consist of 20 to 50 amino acid residues and wherein at least one fragment is derived from amino acid residues 1 to 50 of the mature allergen and at least one fragment is derived from amino acid residues 240 and ending at the C-terminal end of the mature allergen.Type: GrantFiled: September 20, 2017Date of Patent: March 12, 2024Assignee: WORG PHARMACEUTICALS (ZHEJIANG) CO., LTD.Inventors: Monika Hochradl, Frank Stolz, Angela Neubauer, Rainer Henning, Elijahu Babaev
-
Patent number: 11905329Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.Type: GrantFiled: June 7, 2022Date of Patent: February 20, 2024Assignee: Jounce Therapeutics, Inc.Inventors: George Robert Mabry, III, Stephen Sazinsky
-
Patent number: 11903996Abstract: The invention relates generally to a modified human C3 protein containing a number of single amino acid changes in the ? and ?-chain of human C3 protein, designed to increase the affinity of the modified protein to factor B or Bb, to decrease the affinity of the modified protein to factor H, and to reduce the immunogenicity of the modified protein as compared to the native human C3 protein, a nucleotide sequence encoding the modified C3 protein, a plasmid or viral vector containing the nucleotide sequence for expression the modified C3 protein, and a host cell containing the plasmid or viral vector.Type: GrantFiled: October 7, 2016Date of Patent: February 20, 2024Inventors: David C. Fritzinger, Daniel E. Benjamin
-
Patent number: 11897945Abstract: The present disclosure provides methods for treating, preventing, or ameliorating one or more symptoms of birch allergy or allergic disease in a subject by administering to the subject an antibody or antigen-binding fragment thereof that binds Bet v 1, or a cocktail of antibodies or antigen-binding fragments thereof that bind Bet v 1.Type: GrantFiled: June 30, 2021Date of Patent: February 13, 2024Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Amanda Atanasio, Gary Herman, Meagan P. O'Brien, Jamie M. Orengo, Lorah Perlee
-
Patent number: 11891444Abstract: NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.Type: GrantFiled: May 10, 2021Date of Patent: February 6, 2024Assignee: INNATE PHARMAInventors: Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
-
Patent number: 11891439Abstract: The invention provides CCL14 antibodies.Type: GrantFiled: December 28, 2018Date of Patent: February 6, 2024Assignee: Astute Medical, Inc.Inventors: Ravi A Vijayendran, Hua Wang
-
Patent number: 11891452Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.Type: GrantFiled: August 4, 2020Date of Patent: February 6, 2024Assignee: Celldex Therapeutics, Inc.Inventors: Yaron Hadari, Elizabeth M Mandel-Bausch, Francis Joseph Carr, Timothy David Jones, Laura Clare Alexandra Perry
-
Patent number: 11884743Abstract: A variable region sequence of a specific antibody against clothianidin is provided. A gene encoding a heavy chain variable region of the antibody has an amino acid sequence shown in SEQ ID NO: 2. An intact recombinant antibody against clothianidin is provided. The intact recombinant antibody includes a heavy chain constant region, a heavy chain variable region, a light chain constant region and a light chain variable region, wherein a gene encoding the heavy chain variable region has an amino acid sequence shown in SEQ ID NO: 2. An immunostrip containing the antibody for rapid detection of clothianidin residue is also provided. The sequence genes obtained are linked to an expression vector containing a heavy chain constant region gene and a light chain constant region gene, respectively, and an intact recombinant antibody is expressed and obtained by using mammalian cells with a double-plasmid system.Type: GrantFiled: October 16, 2020Date of Patent: January 30, 2024Assignee: Zhejiang UniversityInventors: Yirong Guo, Yunyun Chang, Rubing Zou, Ying Zhao, Shasha Jiao, Guonian Zhu
-
Patent number: 11884735Abstract: Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.Type: GrantFiled: February 3, 2023Date of Patent: January 30, 2024Assignee: TENEOBIO, INC.Inventors: Nathan Trinklein, Katherine Harris, Kyle Lorentsen, Harbani Kaur Malik Chaudhry, Kaitlyn Loughlin
-
Patent number: 11806318Abstract: The present invention provides methods and compositions for the stimulation of immune responses and for treating or preventing allergic disease and responses and inflammatory disease and responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses that prevent or treat allergic disease by reducing allergic response. Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.Type: GrantFiled: July 6, 2021Date of Patent: November 7, 2023Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: James R. Baker, Jr., Anna U. Bielinska, Douglas Smith, Paul E. Makidon, Jessica J. O'Konek
-
Recombinant intravenous immunoglobulin (RIVIG) compositions and methods for their production and use
Patent number: 11801286Abstract: Compositions of recombinant intravenous immunoglobulin (rIVIG) proteins and methods for purification and use of rIVIG proteins. The compositions comprise oligomeric Fc molecules which bind to Fc receptors with high avidity. The rIVIG proteins are useful as immunomodulatory molecules for the treatment of immune disorders including autoimmune diseases, such as refractory immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, lupus, Graves Disease, Kawasaki disease, dermatomyositis, myasthenia gravis, Guillain-Barre syndrome, autoimmune hemolytic anemia, and other immune and inflammatory conditions. The rIVIG proteins can also be used as immunomodulators in patients to reduce the immune rejection of organ transplants, stem cell transplants and bone marrow transplantation.Type: GrantFiled: March 29, 2022Date of Patent: October 31, 2023Assignee: AB Biosciences, Inc.Inventors: Yen-Ming Hsu, Jeng-Shin Lee, Hsiu-Ching Chang -
Patent number: 11786459Abstract: A kit for the sequential early introduction to an infant of at least two allergens to decrease the infant's risk for developing allergies, the kit including an initial lower, exposure dose of a first allergen to be taken for a day or two, a higher maintenance dose of the first allergen to be taken for several days, a maintenance dose of the first allergen and an initial lower, exposure dose of a second allergen to be taken for a day or two, and the higher maintenance dose of the first allergen and a higher maintenance does of the second allergen to be taken for several days. The allergens can be provided in powdered protein form in premeasured pouches for addition to baby formula or to mother's milk. Alternatively, the allergens can already be provided in baby formula, or in other foods such as snack bars, cookies, or gels.Type: GrantFiled: November 25, 2020Date of Patent: October 17, 2023Assignee: PROLLERGY CORPORATIONInventors: Andrew Leitner, Katie Marks, Aaron Rowe, Daniel Zakowski
-
Patent number: 11780924Abstract: The present invention relates to an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules and uses thereof. In particular, targeting of an antigen to antigen presenting cells with the HLAII-specific targeting unit provided herein find use in enhancing immune responses after vaccination.Type: GrantFiled: June 21, 2017Date of Patent: October 10, 2023Assignees: UNIVERSITY OF OSLO, NYKODE THERAPEUTICS ASAInventors: Gunnveig Grodeland, Bjarne Bogen, Agnete B. Fredriksen
-
Patent number: 11773168Abstract: The present invention features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.Type: GrantFiled: December 13, 2018Date of Patent: October 3, 2023Assignee: MOMENTA PHARMACEUTICALS, INC.Inventors: Leona E. Ling, Darrell Nix, Nicholas A. Cilfone
-
Patent number: 11767358Abstract: Provided herein are antibodies that bind Fagales allergens, Fagales related allergens, birch pollen, or Bet v 1, compositions comprising the antibodies, nucleic acids encoding the antibodies, and methods of using the antibodies. According to certain embodiments, the antibodies are fully human monoclonal antibodies that bind to Bet v 1. The antibodies are useful for binding Bet v 1 in vivo, thus preventing binding of the allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the Fagales allergens in sensitized individuals.Type: GrantFiled: August 28, 2020Date of Patent: September 26, 2023Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Jamie M. Orengo, Andrew J. Murphy, Ashok T. Badithe, Vishal Kamat, Yashu Liu
-
Patent number: 11759498Abstract: Mite proteins according to an aspect may be used in diagnosing allergic diseases. Results of diagnosing allergic diseases by using the proteins have high reliability and validity. Further, the proteins may be used in a composition for preventing or treating allergic diseases.Type: GrantFiled: May 4, 2021Date of Patent: September 19, 2023Assignee: Industry-Academic Cooperation Foundation, Yonsei UniversityInventors: Kyoung Yong Jeong, Kyung Hee Park, Jung Won Park, Chang Ook Park, Kwang Hoon Lee